One of the challenges is that we struggle with “pharmacare” as a term. We hear it a lot, but it's sort of seeking a definition. It could mean making having a very all-encompassing program making many products available for coverage, or it could be highly restrictive. If it gets highly restrictive and it's very difficult to make drugs available, I wouldn't say that the drugs wouldn't necessarily get filed to come to Canada. That may happen from time to time, but the speed at which they would choose to file them in Canada might in fact slow down. This means the drug might be available in the world and still take that much longer for Canadians to have access to it.
On June 6th, 2016. See this statement in context.